Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDGFRB | P09619 | 1/20 | 0.55 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.55 |
| ▸ | FGFR2 | P21802 | 4/20 | 0.49 |
| ▸ | EGFR | P00533 | 1/20 | 0.49 |
| ▸ | SRC | P12931 | 1/20 | 0.47 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19711772 | 0.98 | PDGFRB (0.54) | PDGFRBPDGFRAFGFR2EGFRSRC | |
| SCHEMBL4400367 | 0.83 | PDGFRB (0.72) | PDGFRBPDGFRAFGFR2EGFRSRC | |
| SCHEMBL23368184 | 0.79 | ENPP1 (0.72) | EGFRSRC | |
| SCHEMBL7487419 | 0.75 | PDGFRB (0.70) | PDGFRBPDGFRAFGFR2EGFRSRC | |
| SCHEMBL7485861 | 0.75 | EGFR (0.66) | PDGFRBPDGFRAFGFR2EGFRSRC | |
| SCHEMBL25835223 | 0.75 | MCHR1 (0.38) | EGFR | |
| SCHEMBL22570750 | 0.75 | PDGFRB (0.54) | PDGFRBPDGFRAFGFR2EGFRSRC | |
| SCHEMBL9605610 | 0.74 | PDGFRB (0.53) | PDGFRBPDGFRAFGFR2EGFRSRC | |
| SCHEMBL10296327 | 0.74 | PDGFRB (0.56) | PDGFRBPDGFRAFGFR2EGFR | |
| SCHEMBL15309998 | 0.74 | SRC (0.53) | PDGFRBPDGFRAFGFR2SRCTGFBR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200331860-A1 | C-Met Modulators and Methods of Use | EXELIXIS INC (US) | 2020-10-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200331860-A1 | C-Met Modulators and Methods of Use | FLT4, FLT1, MET | PDGFRB 30/4885PDGFRA 63/4885FGFR2 590/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.